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United KingdomABSTRACT We have previously shown that FKBP12 associates with RyR2 in cardiac muscle and that it modulates RyR2
function differently to FKBP12.6. We now investigate how these proteins affect the single-channel behavior of RyR1 derived
from rabbit skeletal muscle. Our results show that FKBP12.6 activates and FKBP12 inhibits RyR1. It is likely that both proteins
compete for the same binding sites on RyR1 because channels that are preactivated by FKBP12.6 cannot be subsequently
inhibited by FKBP12. We produced a mutant FKBP12 molecule (FKBP12E31Q/D32N/W59F) where the residues Glu
31, Asp32,
and Trp59 were converted to the corresponding residues in FKBP12.6. With respect to the functional regulation of RyR1 and
RyR2, the FKBP12E31Q/D32N/W59F mutant lost all ability to behave like FKBP12 and instead behaved like FKBP12.6.
FKBP12E31Q/D32N/W59F activated RyR1 but was not capable of activating RyR2. In conclusion, FKBP12.6 activates RyR1,
whereas FKBP12 activates RyR2 and this selective activator phenotype is determined within the amino acid residues Glu31,
Asp32, and Trp59 in FKBP12 and Gln31, Asn32, and Phe59 in FKBP12.6. The opposing but different effects of FKBP12 and
FKBP12.6 on RyR1 and RyR2 channel gating provide scope for diversity of regulation in different tissues.INTRODUCTIONFK506-binding proteins (FKBPs) bind tightly to ryanodine
receptor (RyR) channels in cardiac and skeletal muscle,
and evidence suggests that they play an important regulatory
role that is impaired in disease, for example, in heart failure
(1–4) and certain skeletal muscle disorders (5). It is reported
that FKBPs provide a stabilizing effect on RyR channel
function by lowering open probability (Po) and preventing
subconductance state gating and that, at the cellular level,
this leads to fewer leaky RyR channels and fewer aberrant
Ca2þ-release events (6–8). It is generally thought that
FKBP12 stabilizes RyR1 and FKBP12.6 stabilizes RyR2
(1,9–11). This is a controversial area, however, because
not all investigators agree that low Po or substate gating in
RyR channels is dependent on the binding of FKBPs (12–
15). Moreover, we have recently shown that FKBP12 binds
with high affinity to RyR2, causing channel activation and
stimulating Ca2þ-induced Ca2þ-release in isolated cardiac
myocytes (15). We demonstrated that FKBP12.6 cannot it-
self lower RyR2 Po, but because it is a partial agonist of
very low efficacy, it can act as an antagonist of FKBP12
and indirectly reduce RyR2 Po and sarcoplasmic reticulumSubmitted October 5, 2013, and accepted for publication December 19,
2013.
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Open access under CC BY-NC-ND license.(SR) Ca2þ-release in cardiac cells. Thus, the gating of RyR2
in cardiac muscle is under the dual modulation of FKBP12
and FKBP12.6, rather than the exclusive influence of
FKBP12.6.
Other experiments also suggest that FKBP12 and
FKBP12.6 do not selectively regulate RyR1 and RyR2,
respectively. In an FKBP12 knockout mouse model, skeletal
muscle function appeared normal, whereas cardiac hyper-
trophy and disturbances in cardiac excitation-contraction
coupling were very severe (16). It has also been shown
that FKBP12.6 can affect skeletal muscle function (17–19)
indicating that, similar to RyR2 in cardiac muscle, RyR1
may also be subjected to dual regulation by FKBP12 and
FKBP12.6.
We have therefore investigated how FKBP12 and
FKBP12.6 affect the single-channel behavior of RyR1
and, to understand the mechanisms underlying their func-
tional effects, we have made direct comparisons of their
effects on RyR2 gating. FKBP12 and FKBP12.6 share the
same number of amino acids (108) and with 82% sequence
identity have similar molecular masses (11.8 kDa,
FKBP12.6; 11.9 kDa, FKBP12 (15)). X-ray crystallography
highlights the close structural similarity of the two proteins,
providing few clues about the residues that may be impor-
tant for binding to RyR1 and RyR2 or for transducing
distinct functional effects. Previous work has indicated
that the residues Gln3, Arg18, and Met49 are necessary
for FKBP12 binding to RyR1 (20). Likewise, mutation of
Asp37 to Val or Ser is reported to enhance the affinity of
FKBP12.6 for RyR2 (21,22). Although affinity is important,
the particular amino acid residues important for efficacyhttp://dx.doi.org/10.1016/j.bpj.2013.12.041
FKBP Activation of RyR1 and RyR2 825(the ability of FKBP12/12.6 to act as agonist or antagonist
of RyR1/RyR2) have not been investigated previously. By
locating the steric and electrostatic differences between
FKBP12 and FKBP12.6 we identified three amino acid
residues that could be relevant in this respect. We generated
a mutant FKBP12 molecule (FKBP12E31Q/D32N/W59F), in
which these three residues were mutated to the corre-
sponding residues found in FKBP12.6 and investigated if
the mutant possessed increased or decreased ability to act
as an activator (agonist) of RyR1 and/or RyR2.
We find that FKBP12 is an inhibitor of RyR1 but an acti-
vator of RyR2. Conversely, FKBP12.6 is an activator of
RyR1 but has barely detectable ability to activate RyR2.
The triple mutant, FKBP12E31Q/D32N/W59F, lost all ability
to activate RyR2 and inhibit RyR1 but instead, caused sig-
nificant activation of RyR1. Thus, the ability for conferring
selectivity of RyR agonist behavior is contained within a
few key amino acids.MATERIALS AND METHODS
Isolation of membrane fractions and bilayer
techniques
Heavy sarcoplasmic reticulum (HSR) vesicles were obtained from sheep
hearts (collected from an abattoir) or rabbit skeletalmuscle, as described pre-
viously (23). SR vesicles were fused with planar phosphatidylethanolamine
lipid bilayers as described (23). Incorporation of RyR always occurred in the
same fixed orientation with the cis side corresponding to the cytosolic chan-
nel side and the trans side to the luminal face. The trans-chamber was held at
ground and the cis-chamber clamped at potentials relative to ground. After
fusion, the cis-chamber was perfused with 250 mM HEPES, 80 mM Tris,
10mMfreeCa2þ, pH7.2. The trans-chamberwas perfusedwith 250mMglu-
tamic acid and 10 mM HEPES, pH to 7.2 with Ca(OH)2 (free [Ca
2þ],
~50 mM). Experiments were performed at 225 2C. Free [Ca2þ] and pH
were maintained constant during experiments and were determined using
a Ca2þ electrode (Orion 93–20, Thermo Fisher Scientific Inc., Waltham,
MA) and Ross-type pH electrode (Orion 81–55, Thermo Fisher Scientific
Inc., Waltham, MA) as previously described (23). FKBP12 and FKBP12.6
were added to the cis-chamber. Both proteins were stored in a buffer contain-
ing 10mMHEPES, 50mMNaCl, 0.5mMDTTand volumes added to the cis-
chamber were <2% of the total volume. Control experiments demonstrated
that the buffer alone caused no effects on RyR function. Rapamycin treat-
ment of the skeletal HSR membrane fraction was obtained by incubating
vesicles with 20 mM rapamycin for 15 min at 36C. Following incubation,
the membrane fraction was sedimented at 180,000  g for 15 min at room
temperature.Data acquisition and analysis
Single-channel currents were monitored under voltage-clamp conditions
using a BC-525C amplifier (Warner Instruments, Hamden, CT). Channel
recordings were low-pass filtered at 10 kHz with a 4-pole Bessel filter, digi-
tized at 100 kHz using an ITC-18 data acquisition interface (HEKA Elek-
tronik, Lambrecht/Pfalz, Germany) and recorded on a computer hard drive
using WinEDR 3.05 software (John Dempster, University of Strathclyde,
UK). The recordings were subsequently filtered at 800 Hz (3 dB) using
a low-pass digital filter implemented in WinEDR 3.05. Channel events
were detected by the 50% threshold method (24) using TAC 4.2.0 software
(Bruxton, Seattle, WA). Po and lifetime distributions were calculated from
3 min of continuous recording using TACfit 4.2.0 software (Bruxton). Podiary plots were obtained using Clampfit 10.2 (Molecular Devices,
Sunnyvale, CA).Preparation of wild-type and mutant FKBPs
Human FKBP12 and rabbit FKBP12.6 were cloned, expressed, and purified
as previously described (15). The preparation of FKBP12E31Q/D32N/W59F
triple mutant is described in the Supporting Material. FKBP12 was also
purchased from Sigma-Aldrich (Dorset, UK).Statistics
Data are expressed as mean 5 SE where n R4. For n ¼ 3, SD is given.
Where appropriate, Student’s t-test was used to assess the difference
between treatments. Where multiple treatments were compared, analysis
of variance followed by a modified t-test was used to assess the difference
between treatments. A p value of <0.05 was taken as significant.Materials
All chemicals were obtained from VWR (Poole, UK) or Sigma-Aldrich. All
solutions were prepared in MilliQ deionized water (Millipore, Harrow, UK)
and those for use in bilayer experiments were filtered through a Millipore
membrane filter with 0.45 mm pore diameter.RESULTS
We have previously demonstrated that both FKBP12
and FKBP12.6 behave as very high affinity, partial agonists
of RyR2 (15). FKBP12 activates RyR2 at low picomolar
concentrations. In contrast, the stimulatory effects of
FKBP12.6 on RyR2 are usually imperceptible because
although FKBP12.6 can bind to RyR2, it has extremely
low efficacy. The Supporting Material (Fig. S1) shows
typical examples of how FKBP12 and FKBP12.6
affect RyR2 gating. To make direct comparisons, identical
recording conditions were used to investigate the effects
of FKBP12 and FKBP12.6 on rabbit skeletal RyR1 gating.
Unexpectedly, FKBP12.6 caused an increase in RyR1 Po.
This effect was irreversible on the timescale of a single-
channel experiment as washout of protein from the cyto-
solic chamber did not lower Po (Fig. 1 A). The irreversibility
of the FKBP12.6 effect suggests a high affinity interaction
between FKBP12.6 and RyR1 and this is confirmed by the
fact that concentrations as low as 10 pM FKBP12.6 can
significantly increase Po. Fig. 1 B shows the mean data
for different concentrations of FKBP12.6. The mean open
and closed times derived from experiments where only
single channels were present in the bilayer were 1.68 5
0.35 ms and 91.2 5 34.9 ms, respectively, before and
2.26 5 0.27 ms and 58.4 5 37.3 ms (SD; n ¼ 3), respec-
tively, after addition of 200 nM FKBP12.6 indicating that
FKBP12.6 primarily increases channel opening frequency
with little effect on open lifetime duration. Lifetime analysis
(see Fig. S2) confirms this mechanism of action; the open
lifetime distribution is not altered even at high concentra-
tions of FKBP12.6.Biophysical Journal 106(4) 824–833
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FIGURE 1 FKBP12.6 activates rabbit skeletal RyR1. (A) A typical
single-channel experiment showing marked activation of RyR1 by 10 pM
FKBP12.6. The bottom trace shows washout of FKBP12.6 from the cyto-
solic chamber. Po values are indicated. Dashed lines indicate open (O1,
O2) and closed (C) channel levels, respectively. (B) Mean Po data obtained
before and after addition of 10 pM, 200 nM, and 1 mM FKBP12.6 (SE; n ¼
5–11; ***p < 0.001; *p < 0.05). Each concentration represents a set of
independent experiments. To see this figure in color, go online.
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FIGURE 2 Inhibitory effects of FKBP12 on rabbit skeletal RyR1. (A) A
representative experiment showing that RyR1 Po is reduced by 500 nM
FKBP12. The bottom trace shows that perfusion of the cis chamber back
to control solutions did not reverse the reduction in Po. The dashed lines
indicate open (O) and closed (C) channel levels, respectively. Po values
are indicated above each trace. (B) Mean data showing that 500 nM
FKBP12 inhibits RyR1 activity (SE; n ¼ 8; *p < 0.05). (C) Diary plot
showing RyR1 Po in the presence of 10 mM cytosolic Ca2þ (control), after
addition of 500 nM FKBP12 and after cis chamber perfusion back to control
solutions. Single-channel traces were subdivided into 10 s sections and Po
was measured for each section and plotted against time. Note that even
during control periods, RyR1 channels display marked variability of gating
over time with random switching between low and high Po modes. The bars
indicate the times of incubation with FKBP12 and washout of FKBP12. To
see this figure in color, go online.
826 Venturi et al.In contrast, FKBP12 always reduced the Po of RyR1. A
typical experiment is shown in Fig. 2Awithmean data shown
in Fig. 2 B. Washout of cytosolic solutions to remove
unbound FKBP12 did not reverse the inhibition as shown
in the bottom trace. In four experiments where FKBP was
washed out and Po was recorded for a further 3 min, Po
was 0.0075 0.005 before and 0.0025 0.001 (SE; n ¼ 4)
after washout. The diary plot of channel activity during a
typical experiment is shown in Fig. 2 C. This illustrates the
modal gating that is characteristic of RyR channels (25,26)
and the irreversibility of the effect of FKBP12. Detailed life-
time analysis was not possible because of the low number of
events that occurred after addition of FKBP12. However,
mean open and closed times were 2.41 5 0.16 ms and
22.9 5 3.94 ms (SE; n ¼ 4), respectively, before and
2.045 0.04 ms and 3325 142 ms (SE; n¼ 4), respectively,
after the addition of 500 nM FKBP12 showing that the main
effect of FKBP12 is to reduce channel opening frequency.
It is generally assumed that FKBP12.6 is not important for
RyR1 function in skeletal muscle because FKBP12.6 is pre-Biophysical Journal 106(4) 824–833sent at very low levels, whereas FKBP12 is present at micro-
molar levels (1–3 mM) (12,27,28). The data shown in Fig. 1,
however, indicates that activation of RyR1 results from a
high affinity interaction with FKBP12.6 and so an important
question to answer is whether FKBP12 and FKBP12.6 could
compete for the same binding sites. If so, then preaddition
of FKBP12.6 should prevent FKBP12 from causing the
immediate inhibition of RyR1 that is shown in Fig. 2 C.
Fig. 3 A and B confirm that this is the case. Preaddition of
FKBP12.6 (200 nM) prevents FKBP12 (500 nM) from
causing channel inhibition (on the timescale of a single-
channel experiment). There are two further issues to
consider. 1), If the affinities of FKBP12/FKBP12.6 for
RyR1 are as high as Figs. 1 and 2 suggest and the dissocia-
tion of FKBPs from RyR1 is very slow, then even picomolar
quantities of either isoform should prevent the binding of the
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FIGURE 3 Preaddition of FKBP12.6 prevents the inhibition of rabbit
skeletal RyR1 by FKBP12. (A) A representative diary plot of RyR1 Po
changes following preincubation with 200 nM FKBP12.6 and subsequent
addition of 500 nM FKBP12 (incubation periods are shown by the bars).
Control solutions contained 10 mM cytosolic Ca2þ as the sole channel
activator. Subsequent addition of 500 nM FKBP12 did not override the acti-
vating effects of FKBP12.6. After washout of the cis chamber, Po was not
completely reversed to control values. (B) Bar chart showing the mean Po
data for control, preaddition of 200 nM FKBP12.6, subsequent addition of
500 nM FKBP12, and washout to control solutions (SE; n ¼ 4). Pretreat-
ment with picomolar levels of FKBP12.6 (C) or FKBP12 (D) at the 10:1
ratio of FKBP12:FKBP12.6 that is expected in situ, was able to block the
subsequent addition of the other FKBP isoform (SE; n ¼ 10–11; *p <
0.05). To see this figure in color, go online.
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FIGURE 4 Comparison of FKBP12 and FKBP12.6 proteins to highlight
the amino acid substitutions of the FKBP12E31Q/D32N/W59F mutant. (A)
Amino acid sequence alignments of human FKBP12, human FKBP12.6,
and FKBP12E31Q/D32N/W59F. The residues of FKBP12 and FKBP12.6 that
differ are highlighted in blue. The red arrows indicate the three amino
acid residues that were substituted into the FKBP12E31Q/D32N/W59F mutant.
(B) Overlaid ribbon diagrams of human FKBP12 and human FKBP12.6
based on their crystal structures (RCSB PDB accession codes 2DG3 and
1C9H, respectively) showing the three residues highlighted as most
likely relevant amino acid substitutions between the two proteins. The
dashes indicate these residues: Glu31 in FKBP12 is replaced by Gln31
from FKBP12.6 (E31Q); Asp32 in FKBP12 is replaced by Asn32 from
FKBP12.6 (D32N); Trp59 in FKBP12 is replaced by Phe59 from
FKBP12.6 (W59F). Mammalian FKBP12 and FKBP12.6 are highly
conserved and Fig. S3 shows sequence alignment of several species demon-
strating that the three residues that we chose to mutate were absolutely
conserved in FKBP12 and were different but, again, absolutely conserved
in FKBP12.6.
FKBP Activation of RyR1 and RyR2 827other isoform. 2), Physiological levels of FKBP12 are likely
to be at least 5–10 times the levels of FKBP12.6, therefore,
what happens in the competition studies if FKBP12 is
present at 10 times the levels of FKBP12.6? To address
these questions, we have performed experiments at 10 pM
FKBP12.6 and 100 pM FKBP12 (pretreating first with
10 pM FKBP12.6 (Fig. 3 C) or 100 pM FKBP12
(Fig. 3 D). The experiments demonstrate pharmacological
consistency; the high affinity binding and slow dissociation
rate of either isoform of FKBP blocks the binding of the sub-
sequently added isoform of FKBP.
To identify the amino acid residues in FKBP12 that are
important for the selective ability of FKBP12 to reduce
the Po of RyR1 and increase the Po of RyR2, we compared
the specific amino acids of FKBP12 and FKBP12.6 that
differ. Fig. 4 compares the primary sequences of FKBP12
and FKBP12.6 and their three-dimensional structures(FKBP12 purple; Protein Data Bank (PDB) 2DG3;
FKBP12.6 green; PDB 1C9H) and illustrates their high
structural similarity. Indeed, the root mean-squared devia-
tion between the superimposed backbone atoms is only
0.44 A˚. On the basis of their steric and electrostatic proper-
ties, we identified three residues that could have particular
relevance. Glu31 and Asp32 are negatively charged resi-
dues of FKBP12, whereas the corresponding residues
in FKBP12.6 are neutral (Gln31 and Asn32). Trp59 in
FKBP12 is located within the hydrophobic binding pocket
for rapamycin and has a larger side chain (an indole)
compared with Phe59 (a phenyl group) in FKBP12.6. The lo-
cations of these three amino acid residues in FKBP12 and
the corresponding residues in FKBP12.6 are highlighted.Biophysical Journal 106(4) 824–833
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828 Venturi et al.We produced a triple mutant of FKBP12 where these three
highlighted amino acids were mutated to the corresponding
residues in FKBP12.6 thus converting Glu31 to Gln, Asp32 to
Asn, and Trp59 to Phe. The affinity of various mutants of
FKBPs for RyR proteins have previously been investigated,
(20,29) although the ability to influence RyR single-channel
function (efficacy) has not been studied. The FKBP12E31Q/
D32N/W59F triple mutant retains affinity for RyR channels
(20,29) and therefore is a molecule of choice for studying
efficacy (because we must use mutant molecules that bind
to RyR channels to study efficacy).
We then investigated the ability of FKBP12E31Q/D32N/W59F
to influence the gating of RyR1 and RyR2 under identical
experimental conditions to those used with the wild-type
proteins. Representative examples of the effects of
FKBP12E31Q/D32N/W59F on RyR2 gating are shown in
Fig. 5. FKBP12E31Q/D32N/W59F produced no observable
changes in RyR2 gating even at nanomolar or micro-
molar concentrations. Clearly, the triple mutant protein,
FKBP12E31Q/D32N/W59F, has lost the normal ability of
FKBP12 to activate RyR2 and behaves instead like
FKBP12.6; efficacy has been lost.
When FKBP12E31Q/D32N/W59F was added to RyR1 chan-
nels, an increase in Po was observed (Fig. 6), very similar
to that observed with FKBP12.6 (see Fig. 1). The representa-A C 
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FIGURE 5 Effects of FKBP12E31Q/D32N/W59F on sheep cardiac RyR2
gating. A and B are typical examples of single-channel experiments demon-
strating that neither 200 nM (A) or 1 mM (B) FKBP12E31Q/D32N/W59F cause
any observable effects on RyR2 activity. Dashed lines indicate open (O) and
closed (C) channel levels, respectively. Po values are indicated. C and D
illustrate mean Po before and after addition of 200 nM (C) and 1 mM (D)
FKBP12E31Q/D32N/W59F, respectively (SE; n¼ 5). To see this figure in color,
go online.
FIGURE 6 FKBP12E31Q/D32N/W59F activates rabbit skeletal RyR1. (A) A
typical experiment showing that 1 mM FKBP12E31Q/D32N/W59F activates
RyR1. The effects were not reversed after washout of the cis chamber
(bottom trace). Open (O1, O2) and closed (C) channel levels are marked
with dashed lines. (B) Diary plot of a typical RyR1 single-channel experi-
ment. After washout of the cis chamber, Po did not reverse to control values.
The bars indicate the incubation timewith themutant protein and subsequent
washout of the protein from the cis chamber. (C) Mean Po values before
and after addition of 200 nM, 500 nM, and 1 mM FKBP12E31Q/D32N/W59F
(SE; n ¼ 7–11; *p < 0.05). Each concentration represents a set of indepen-
dent experiments. To see this figure in color, go online.
Biophysical Journal 106(4) 824–833tive experiment shown in Fig. 6 A illustrates the increase
in the frequency of channel openings that was induced by
FKBP12E31Q/D32N/W59F and demonstrates that washout of
the mutant protein from the cytosolic chamber could not
reverse the effects of the mutant. To observe the variations
in Po that occur with time, diary plots of Po against time
were recorded (see Fig. 6B). The effects of a range of concen-
trations of FKBP12E31Q/D32N/W59F were investigated and in
all cases, FKBP12E31Q/D32N/W59F activated RyR1 (Fig. 6 C).
It is possible that some endogenous FKBP could still be
associated with the channels in the bilayer before we add
exogenous FKBPs. However, because we observe reproduc-
ible effects with both FKBP12 and FKBP12.6 and at both
RyR1 and RyR2, it is obvious that there are always vacant
FKBP binding sites on both channels that are function-
ally relevant. We do not know how many molecules of
FKBP12 or FKBP12.6 must bind to RyR channels to pro-
duce their effect. The irreversible nature of the binding
makes this difficult to examine at the single-channel level.
FKBP Activation of RyR1 and RyR2 829Many previous reports have used drugs such as rapamycin
or FK-506 to strip FKBPs from RyRs (9,11,30–33). How-
ever, even in these studies, it was not possible to be certain
that all FKBP molecules were removed because Western
blot was the only proof of FKBP dissociation and this
is not a technique able to detect low levels of proteins. In
fact, later work shows that these treatments do not achieve
complete displacement of bound FKBPs (34,35). We have
therefore treated SR vesicles with rapamycin (20 mM) using
previously published methods (30) and performed mass
spectrometry to detect the FKBPs because this is a more
sensitive method of protein detection than Western blot
analysis. We find that FKBP12 is still detected with high
confidence (false discovery rate < 1%; Table S1) demon-
strating that rapamycin treatment does not remove all
FKBP proteins from rabbit skeletal SR. Western blot anal-
ysis shown in Fig. 7, A and B, shows that rapamycin is
very effective at dissociating FKBPs from the SR but that
there is a residual amount left which, depending on theA
C 
B 
D 
FIGURE 7 Rapamycin irreversibly activates rabbit skeletal RyR1. (A)
Immunochemical detection of FKBP associated with skeletal HSR before
(left lane) and after (middle lane) rapamycin treatment (as described in
Methods). HSRwas loaded at a protein concentration of 25mg. Recombinant
purified FKBP12 was loaded at 500 ng as a positive control (right lane).
(B) The percentage of FKBP detected in HSR after rapamycin treatment
(Rap-treated HSR) is compared to control levels (HSR) (SD, n ¼ 3, **p <
0.01). (C) Shows a representative example of a rapamycin pretreated
RyR1 channel reconstituted into a bilayer. (O) and (C) indicate the open
and the closed channel levels, respectively. Addition of 1 mM FKBP12 to
the cytosolic side of the channel (second trace) did not lower Po. Lowering
the cytosolic [Ca2þ] to <1 nM (by addition of 10 mM EGTA) shut the
channel (bottom trace). (D)Mean Po values for control channels (untreated),
rapamycin-treated channels (Rap-treated RyR1), and Rap-treated channels
after addition of 1 mM FKBP12 (Rap-treated RyR1 þ 1 mM FKBP12) are
illustrated (SE; n ¼ 3–7; *p < 0.05). To see this figure in color, go online.sensitivity of the antibody, may not always be immunode-
tectable. In the literature, there is heavy reliance on the abil-
ity of rapamycin to dissociate FKBPs from RyR channels to
infer mechanistic insight into FKBP effects on RyR func-
tion. However, such reasoning is questionable because there
are reports that rapamycin may affect RyR channel behavior
directly (35,36). We have therefore examined if rapamycin
affects RyR1 gating by incorporating the rapamycin pre-
treated SR vesicles into bilayers. In line with the literature,
we find that the Po of RyR1 channels pretreated with rapa-
mycin is significantly higher than that of control channels
(Fig. 7, C and D). Of importance, however, we find that
addition of FKBP12 does not reduce Po values back to con-
trol levels (see second trace and Fig. 7D) suggesting that the
rapamycin-induced elevation of Po was not related to disso-
ciation of FKBP12. The rapamycin-induced increase in
Po was not caused by nonspecific damage to the channels
because lowering cytosolic [Ca2þ] to subactivating levels
(third trace) completely closed the channels showing they
were still sensitive to Ca2þ.
A rapamycin-induced increase in cardiac RyR2 Po has
also been used to infer that dissociation of FKBP12.6
increases RyR2 Po (11) so we performed similar experi-
ments with RyR2 (see Fig. S4). As with RyR1, we found
that rapamycin increased RyR2 activity, although the effect
was more marked. Washout of rapamycin did not lower Po,
nor did the addition of FKBP12.6, although the channels
retained sensitivity to cytosolic Ca2þ and were closed by
reducing [Ca2þ]. Because rapamycin does not fully disso-
ciate FKBP12 from RyR1 and because it irreversibly alters
RyR1 and RyR2 channel gating, these experiments high-
light the need to use native RyR channels that have not
been chemically treated to probe the functional effects of
FKBP12/FKBP12.6.DISCUSSION
To our knowledge, a novel and unexpected finding of this
study is that FKBP12.6 is a potent activator of the rabbit
skeletal RyR1, whereas FKBP12 is an inhibitor. The results
contrast with the situation in cardiac muscle where FKBP12
is an activator of RyR2 and FKBP12.6 is an antagonist of
FKBP12 (15) but does not, itself, lower Po. We performed
site-directed mutagenesis of the FKBP12 molecule and
found that the selective ability of FKBP12 to activate
RyR2 and inhibit RyR1 is contained within the three amino
acid residues; Glu31, Asp32, and Trp59. Mutation of these
key residues to those found in FKBP12.6, caused a complete
switch from FKBP12-like action to FKBP12.6-like action.
Experiments where sequential addition of FKBP12 and
FKBP12.6 are made to the cytosolic face of RyR channels
indicate that these proteins would compete for the same
binding sites on RyR1 and RyR2. This is not surprising
in view of the structural similarity of FKBP12 and
FKBP12.6 but also in the light of cryo-electron microscopyBiophysical Journal 106(4) 824–833
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indicating that FKBPs bind within similar binding pockets
on RyR1 and RyR2 (37–39). Use of fluorescence resonance
energy transfer also suggests that FKBP12 and FKBP12.6
would bind in the same locations on RyR1 and RyR2 and
with similar orientation (40).
We show that FKBP12 and FKBP12.6 exert different
effects on the gating of both RyR1 and RyR2. This indicates
that the binding sites on the RyR1 and RyR2 channel pro-
teins could be composed of different amino acid residues.
Confirmation of this idea comes from binding studies
(12,28) using radiolabeled FKBP12/12.6, which indicate
that canine cardiac and rabbit skeletal RyR have different
affinity for FKBP12/12.6 (although it should be remem-
bered that subsequent work demonstrated that canine
RyR2 has unusually high affinity for FKBP12.6 that is not
shared by other mammalian RyR2 isoforms (41)). Another
explanation for the different functional effects of FKBP12/
12.6 could be that the binding interactions between
FKBPs/RyR1 and FKBPs/RyR2 produce different changes
in channel gating simply because of subtle differences in
RyR1 and RyR2 channel gating mechanisms. For example,
RyR1 and RyR2 are regulated slightly differently by cyto-
solic Ca2þ, especially at inactivating [Ca2þ] (42–44), and
there are subtle differences in the mechanisms by which
other ligands such as ATP, caffeine, or suramin activate
RyR1 and RyR2 (45–48). We show that activation of
RyR1 by FKBP12.6 involves an increase in the frequency
of channel opening. This is similar to the mechanism by
which cytosolic Ca2þ activates RyR1 (49) and therefore
FKBP12.6 may be sensitizing the channel to cytosolic
Ca2þ. We have previously demonstrated that FKBP12 sen-
sitizes RyR2 to cytosolic Ca2þ (15) and therefore this may
be a common mechanism by which FKBPs regulate RyR
channels. We cannot be so confident about the mechanism
by which FKBP12 inhibits RyR1; it may reduce RyR1
sensitivity to cytosolic Ca2þ but because Po is lowered so
much, we cannot collect enough opening events for lifetime
analysis. The important, take-home message, though, is that
FKBP12 and FKBP12.6 drive Po in opposite directions for
both RyR1 and RyR2. This has important consequences for
skeletal muscle function if the relative ability of FKBP12
and FKBP12.6 to bind to RyR1 is affected in stress, exer-
cise, aging, or disease.
Although we and others have previously reported that
FKBP12.6 does not, itself, reduce the Po of RyR2
(12,14,28), opinion to the contrary still persists. Our exper-
iments with rapamycin now indicate why this could be.
Rapamycin is a frequently used tool for dissociating FKBPs
from RyR channels and irreversible increases in RyR Po
after rapamycin treatment have led to the conclusion
that RyRs must be bound by FKBPs to ensure stable low
Po channel gating (11,31,35,50). However, FKBP12 or
FKBP12.6 was not added back in the bilayer experiments
to examine if these proteins could reverse a rapamycin-Biophysical Journal 106(4) 824–833induced increase in Po. We have now demonstrated that
use of rapamycin may produce misleading results because
it can irreversibly increase RyR Po in a manner that is inde-
pendent of the presence or absence of FKBPs. FK506 is
another drug, used extensively to dissociate FKBPs from
RyRs. However, studies conducted on intact skeletal fibers
have also shown effects of both rapamycin and FK506
on excitation-contraction coupling that are unrelated to the
removal of FKBPs (51,52). Again, incorrect conclusions
could be drawn from using this compound if it was not
completely removed during a subsequent experiment.
Another problem is that [3H]ryanodine binding has often
been used to indicate RyR channel activity following
rapamycin treatment rather than examining the detailed
single-channel behavior of RyR1/RyR2 channels directly
following incorporation into bilayers. [3H]ryanodine bind-
ing can provide an incorrect approximation of the effect of
an intervention on RyR activity if that intervention also
directly affects the binding of ryanodine. For example,
calmodulin increases RyR2 Po but decreases [3H]ryanodine
binding because calmodulin also reduces the rate of associ-
ation of ryanodine to RyR2 (53). There is no study that has
investigated whether FKBPs could directly alter the rate of
association or dissociation of ryanodine to RyRs or, partic-
ularly pertinent to this study, whether rapamycin itself influ-
ences ryanodine binding independently of Po. It is very
relevant that a single-channel report by Ahern et al. (1997)
(33) suggests that ryanodine modification of RyR1 may be
reversible after treatment with FK506. Any such increase
in the rate of dissociation of ryanodine from RyR channels
would, naturally, affect the binding of [3H]ryanodine to car-
diac or skeletal SR. We (and others (34,35)) have also shown
that rapamycin-treated skeletal SR vesicles will still have re-
sidual FKBP12 molecules associated (even if below immu-
nodetection levels) and this will be a significant confounding
factor given the very high affinity of FKBPs for RyR chan-
nels. Endogenous FKBPs will be present within the incuba-
tion medium for the [3H]ryanodine binding assay and will
already be bound to an unquantified number of RyR chan-
nels. Using [3H]ryanodine binding to skeletal SR vesicles
to assay the functional actions of FKBPs will therefore pro-
vide results that are difficult to interpret.
Our mutant experiments have begun to distinguish those
regions of the FKBP proteins that are important for efficacy.
The FKBP12 mutant, FKBP12E31Q/D32N/W59F, clearly has
efficacy as an activator of RyR1 but appears to have no
or low efficacy as a regulator of RyR2. Our experiments
do not provide accurate measurement of the affinity of
FKBP12E31Q/D32N/W59F for RyR1 or RyR2, however, they
suggest that FKBP12E31Q/D32N/W59F retains high affinity
for both RyR1 and RyR2 because the effects of adding
FKBP12E31Q/D32N/W59F to the cytosolic chamber are irre-
versible after washout (see Fig. 6, A and C), and preaddition
of FKBP12E31Q/D32N/W59F prevents FKBP12 from activating
RyR2 (data not shown). Indeed, this same triple FKBP12
FKBP Activation of RyR1 and RyR2 831mutant has previously been shown to be capable of displac-
ing 35S-labeled FKBPs bound to skeletal and cardiac SR
vesicles indicating that high affinity binding to RyR1 and
RyR2 is retained (29). The FKBP12 single point mutants
E31Q, D32N, and W59F also bind tightly to rabbit skeletal
RyR1 as evidenced by coimmunoprecipitation of GST-
mutant FKBP12 and RyR1 (20). Crystallographic data
show that Trp59 in FKBP12 and Phe59 in FKBP12.6 are
located within the rapamycin hydrophobic binding pocket.
This region is also suggested to provide the hydrophobic
cavity involved in binding RyR channels (37,38,54,55).
Mutations at position 59 in FKBP12/FKBP12.6 clearly do
not abolish the binding of FKBPs to RyRs (20,29), although
some change in affinity is indicated (29). The larger amino
acid in FKBP12 does not alter the fold of the protein but it
could influence the particular interactions between FKBPs
and RyR2 that lead to changes in channel gating.
The residues in position 31 and 32 point away from the
hydrophobic core of the proteins, and there are no structural
differences between FKBP12 and FKBP12.6 in this region,
however these residues could be relevant for electrostatic
reasons, as FKBP12 carries two negative charges very
close to each other, which are not present in FKBP12.6. A
recent publication (39) suggests involvement of electrostatic
charges in the interactions between FKBP12 and RyR1 and
the formation of a salt bridge between Asp32 on FKBP12 and
Arg976 on RyR1, which stabilizes the binding. If this hypoth-
esis is correct, the mutations E31Q and D32N (where two
negative charges in FKBP12 are substituted by the corre-
sponding neutral residues of FKBP12.6), could lead to a crit-
ical change in protein function as these residues may be
crucial for producing the precise binding interactions that
enable FKBP12 to inhibit RyR1 and activate RyR2.Physiological and pathophysiological
perspectives
Our study calls for a fresh evaluation of the roles of FKBPs
in cardiac and skeletal muscle and, in fact, in all tissues
where RyR1 or RyR2 are present. It has generally been
assumed that FKBP12 is the only relevant physiological
regulator of RyR1, whereas FKBP12.6 is the only important
isoform that influences the function of cardiac muscle and
other tissues where RyR2 is expressed. Because our exper-
iments clearly demonstrate that both isoforms of FKBP can
modulate both isoforms of RyR at extremely low concentra-
tions, and since both FKBP12 and FKBP12.6 are present in
skeletal and cardiac cells (12,27,28), SR Ca2þ-release in
cardiac and skeletal muscle may depend on the competitive,
dual regulation by both FKBP12 and FKBP12.6. The litera-
ture reports levels of 1–3 mM FKBP12 in cardiac and skel-
etal muscle but much lower (100–200 nM (56)) or
undetectable (12,27,28) levels of FKBP12.6. Regarding
RyR2, it now appears that canine RyR2 is somewhat of an
outlier in having particularly high affinity for FKBP12.6(41). For all other species of RyR2 investigated, RyR2
appears to also have high affinity for FKBP12 (15,41). In
sheep, mass spectrometry demonstrated that FKBP12 can
be detected in membrane fractions containing RyR2 with
high confidence, whereas FKBP12.6 can only be detected
with low confidence (15). Recent immunoblot analysis
also showed that FKBP12 is present in cardiac cells (and
in membrane fractions containing RyR2) of three mamma-
lian species (pig, rabbit, mouse) at much higher levels
than FKBP12.6 (34). In skeletal muscle, there is evidence
that FKBP12 is more likely to be associated with RyR1
than FKBP12.6 (34,57). However, because FKBP12.6 is
present in skeletal muscle and because we show a functional
effect of FKBP12.6 at very low concentrations, we conclude
that FKBP12.6 may also play a role in regulating RyR1 in
skeletal muscle.
It is clear that the relative level of expression of FKBP12
and FKBP12.6 is important. In this regard, it is notable that
FKBP binding to RyRs has been reported to be reduced in
certain skeletal muscle pathologies (2,3,5). This may reflect
an altered ratio in the expression levels of FKBP12 and
FKBP12.6 or could be due to changes to RyR1 that affect
its relative affinity for FKBP12/FKBP12.6. For example, a
reduction in RyR1/FKBP12 binding as reported for dystro-
phic muscle (5) and sarcopenia (58,59), would be expected
to lead to increased RyR1 Po due to dissociation of FKBP12
(which reduces RyR1 Po) and the possible increased
binding by FKBP12.6 (which increases RyR1 Po). Fig. 8
suggests how the dual regulation of SR Ca2þ-release by
FKBP12 and FKBP12.6 may operate in skeletal muscle
under physiological and pathophysiological conditions.
Our study has clear implications for other tissues where
both RyRs and FKBPs are expressed. We should not as-
sume that FKBP12 will exclusively bind to RyR1 or that
FKBP12.6 will only bind to RyR2, rather, that both proteins
can interact with either RyR isoform and that the absolute
binding stoichiometry may vary from tissue to tissue. There
are many reports indicating that FKBPs play an important
role in intracellular Ca2þ release in a wide range of different
tissues and cell types. These include bladder smooth
muscle (60), pancreatic b-cells (61), vascular smooth mus-
cle (62), endothelial cells (63), and various neuronal cells
(64). Changes to the relative FKBP12/FKBP12.6 expression
level in these cells may have important pathological
implications.CONCLUSION
We have shown that RyR1 is activated by FKBP12.6 but in-
hibited by FKBP12 and use of the FKBP12E31Q/D32N/W59F
mutant demonstrates that efficacy is controlled by very
small changes in FKBP structure. The experiments highlight
the need to understand the functional consequences of
FKBP12/FKBP12.6 binding to RyR channels at the sin-
gle-channel level to recognize the putative physiologicalBiophysical Journal 106(4) 824–833
FIGURE 8 Proposed model of FKBP regulation of SR Ca2þ release in
skeletal muscle. Under normal conditions, evidence suggests that RyR1
is predominantly bound by FKBP12, which maintains RyR1 in a low Po
mode. The occasional binding of FKBP12.6 to RyR1 would lead to a
minority of channels with increased Po. In disease or aging, it is reported
that less FKBP12 is associated with RyR1. We speculate that a greater
fraction of RyR1 channels may be bound by FKBP12.6, which would
increase the numbers of leaky RyR1 channels. To see this figure in color,
go online.
832 Venturi et al.roles of FKBP/RyR interactions in different cell types and
the changes that occur in disease and aging.SUPPORTING MATERIAL
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